Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Hazard ratio (HR) for mortality among patients taking antiplatelet agents compared with those not taking antiplatelet agents, stratified by bearing end-stage cancer

From: Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits

TherapyAdjusted HR (95% CI)
Patients with end-stage cancerPatients without end-stage cancer
Any antiplatelet therapy v.s. Without antiplatelet therapy0.13 (0.03–0.64)0.58 (0.26–1.26)
 Aspirin v.s. Without aspirin0.15 (0.03–0.74)0.52 (0.20–1.34)
 Clopidogrel v.s. Without clopidogrela0.52 (0.15–1.83)
 Cilostazol v.s. Without cilostazola3.41 (0.74–15.7)
  1. Model includes patient’s demographic characteristics, activities of daily living (ADL), primary disease requiring home visiting care and the Charlson comorbidity index
  2. Patients without each antiplatelet drug included those who took other antiplatelet drugs than the main drug. (e.g. patients without aspirin composed from those who didn’t take any antiplatelet drugs and those who took either clopidogrel or cilostazol)
  3. a Analyses could not be performed due to limited number of samples
  4. Boldface indicates p value < 0.05